7 reports of this reaction
2.2% of all ALUMINUM CHLORIDE reports
#3 most reported adverse reaction
DERMATITIS ATOPIC is the #3 most commonly reported adverse reaction for ALUMINUM CHLORIDE, manufactured by Clarion Brands, LLC. There are 7 FDA adverse event reports linking ALUMINUM CHLORIDE to DERMATITIS ATOPIC. This represents approximately 2.2% of all 317 adverse event reports for this drug.
Patients taking ALUMINUM CHLORIDE who experience dermatitis atopic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DERMATITIS ATOPIC is a less commonly reported adverse event for ALUMINUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to dermatitis atopic, the following adverse reactions have been reported for ALUMINUM CHLORIDE:
The following drugs have also been linked to dermatitis atopic in FDA adverse event reports:
DERMATITIS ATOPIC has been reported as an adverse event in 7 FDA reports for ALUMINUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DERMATITIS ATOPIC accounts for approximately 2.2% of all adverse event reports for ALUMINUM CHLORIDE, making it one of the most commonly reported side effect.
If you experience dermatitis atopic while taking ALUMINUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.